日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語(yǔ)Fran?ais
World
Home / World / Americas

Remdesivir shows promise in coronavirus trial

By AI HEPING in New York | China Daily Global | Updated: 2020-04-30 13:52
Share
Share - WeChat

 

National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci attends a coronavirus response meeting between US President Donald Trump and Louisiana Governor John Bel Edwards in the Oval Office at the White House in Washington, US, April 29, 2020. [Photo/Agencies]

The antiviral drug remdesivir succeeded in a clinical trial, according to preliminary results released Wednesday, raising hopes it could become the first approved treatment for COVID-19.

Dr Anthony Fauci, chief of the US National Institute of Allergy and Infectious Diseases (NIAID) that released the study and a top adviser on President Donald Trump's White House Coronavirus Task Force, said the result was a strong "proof of concept" for the drug.

The NIAID study observed more than 1,000 patients hospitalized with the coronavirus who were randomly given either remdesivir or a placebo in a controlled trial. Patients taking remdesivir recovered 31 percent faster than those taking the placebo, the study found.

"Although a 31 percent improvement doesn't seem like a knockout 100 percent, it is a very important proof of concept because what it has proven is that a drug can block this virus," Fauci said at the White House.

The typical patient who took remdesivir recovered in 11 days, while the typical patient in the placebo group recovered in 15 days.

Of the patients taking remdesivir, 8 percent died, compared with 11.6 percent of those in the placebo group, though the difference wasn't found to be statistically significant.

"Certainly it's positive, it's a very positive event," Trump said of the results.

The Food and Drug Administration will likely issue an emergency approval for remdesivir, The New York Times reported, citing a senior administration official.

Also on Wednesday, Pfizer said that testing of its coronavirus vaccine could start next week and could be ready by the fall.

NIAID said more information from the trial would be published in a forthcoming report.

Gilead's remdesivir isn't yet licensed or approved in the US or anywhere else in the world.

Remdesivir, which is given as an IV infusion, hasn't previously been approved to treat any diseases although it showed some promise when it was tried on Ebola patients several years ago.

An ampule of Ebola drug remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020. [Photo/Agencies]

In China, a separate trial of remdesivir did not find a meaningful benefit when compared with a placebo, according to results published Wednesday in the medical journal Lancet.

"Unfortunately, our trial found that while safe and adequately tolerated, remdesivir did not provide significant benefits over placebo," said the lead investigator of the new study, Dr Bin Cao of the China-Japan Friendship Hospital and Capital Medical University in Beijing.

That study was ended early because of the difficulty in finding enough COVID-19 patients to enroll in China, the researchers said.

Given that that study didn't reach full enrollment, the results are "inconclusive", said John David Norrie, a professor at the University of Edinburgh, in an accompanying commentary.

Gilead Sciences, the company that developed remdesevir, also released data Wednesday from its own trial of five-day and 10-day regimens of remdesivir in 397 patients with severe forms of COVID-19.

That study did not compare patients who got the drug with those who were given a placebo, making the results more difficult to interpret.

Merdad Parsey, Gilead's chief medical officer, said the results complemented the NIAID's placebo-controlled trial and were intended to help figure out the right dose for patients. The trial generated similar results for patients treated with the five-day course and those treated with the 10-day course, Gilead said.

"The study demonstrates the potential for some patients to be treated with a 5-day regimen, which could significantly expand the number of patients who could be treated with our current supply of remdesivir," Parsey said in a statement.

Using a five-day course could effectively double the number of patients who could be treated with the available supply of remdesivir. The company said that it was already ramping up manufacturing capacity, planning to produce more than 1 million courses by the end of the year.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 天天狠狠色噜噜 | 亚州精品天堂中文字幕 | 四虎国产成人免费观看 | 毛片一区二区三区四区 | 国产综合一区二区 | 国产片在线观看 | 亚洲欧美一级久久精品 | 美女下面被cao出水 玖玖玖影院 | 欧美中文在线视频 | av片在线播放 | 亚洲国产路线1路线2路线 | 亚洲国产精品久久久久秋霞蜜臀 | 新超碰97| 黄在线观看+在线播放 | 99热在线精品观看 | 久久网欧美 | 欧美精品一区二区三区在线 | 国产精品久久久久久日本 | 国产精品亚洲va在线观看 | 成人在线视频一区 | 亚洲精品第一国产综合野 | 国产精品福利视频免费观看 | 久久精品免费视频观看 | 国产乱妇无码大黄AA片 | 亚洲综合在线网 | 久草在线免费新视频 | 黄视频免费在线观看 | 国产综合久久 | 日本高清va不卡视频在线观看 | a视频免费 | 不卡国产一区二区三区四区 | 91看片淫黄大片欧美看国产片 | 欧美激情免费观看一区 | 日日插夜夜操 | 韩漫重考生漫画画免费读漫画下拉式土豪漫 | 欧美综合久久 | 91视频h| www.夜夜骑| 欧美伊人 | 欧美在线一级精品 | 成人网站偷拍澡AAAA |